153 related articles for article (PubMed ID: 31548806)
1. Inter- and intraprovincial inequities in public coverage of cancer drug programs across Canada: a plea for the establishment of a pan-Canadian pharmacare program.
Sorin M; Franco EL; Quesnel-Vallée A
Curr Oncol; 2019 Aug; 26(4):266-269. PubMed ID: 31548806
[No Abstract] [Full Text] [Related]
2. Whither seniors' pharmacare: lessons from (and for) Canada.
Morgan SG; Barer ML; Agnew JD
Health Aff (Millwood); 2003; 22(3):49-59. PubMed ID: 12757272
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy treatment options and policies.
Breshears Wheeler J; Hanson K
NCSL Legisbrief; 2012 May; 20(19):1-2. PubMed ID: 22666895
[No Abstract] [Full Text] [Related]
4. National pharmacare: a dog's tale.
Anis AH
CMAJ; 2004 Sep; 171(6):565-6. PubMed ID: 15367455
[No Abstract] [Full Text] [Related]
5. [Family physicians resist high prescription risk].
Schmidt K
MMW Fortschr Med; 2003 May; 145(20):58. PubMed ID: 12822233
[No Abstract] [Full Text] [Related]
6. Post-Romanow pharmacare: last-dollar first...first-dollar lost?
Morgan SG; Willison DJ
Healthc Pap; 2004; 4(3):10-20. PubMed ID: 15114064
[TBL] [Abstract][Full Text] [Related]
7. Unexpected "donut hole" raises concerns that patients will fail to fill needed prescriptions.
Howard-Ruben J
ONS News; 2006 Dec; 21(12):10-1. PubMed ID: 17193936
[No Abstract] [Full Text] [Related]
8. The Challenges of Canadian Pharmacare Are More Complicated Than Acknowledged Comment on "Pharmacare in Canada".
Acri Née Lybecker KML
Int J Health Policy Manag; 2021 Mar; 10(3):152-154. PubMed ID: 32610780
[TBL] [Abstract][Full Text] [Related]
9. Pharmacare: Are we getting the right medicines?
Attara G
Healthc Manage Forum; 2017 Jul; 30(4):193-196. PubMed ID: 28929869
[TBL] [Abstract][Full Text] [Related]
10. Trudeau signals support for Canadian pharmacare.
Webster P
Lancet; 2019 Jun; 393(10190):2482. PubMed ID: 31232361
[No Abstract] [Full Text] [Related]
11. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558
[No Abstract] [Full Text] [Related]
12. Canadian pharmacare: looking back, looking forward.
Morgan SG; Daw JR
Healthc Policy; 2012 Aug; 8(1):14-23. PubMed ID: 23968600
[TBL] [Abstract][Full Text] [Related]
13. Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?
Coombes ME; Morgan SG; Barer ML; Pagliccia N
Healthc Q; 2004; 7(4):suppl 13-9. PubMed ID: 15540402
[TBL] [Abstract][Full Text] [Related]
14. Restrictions on NHS prescribing in Australia.
Smith T
Br Med J; 1979 Jan; 1(6156):99-100. PubMed ID: 761010
[No Abstract] [Full Text] [Related]
15. Policy choices for pharmacare; the need to examine benefit design, medication management strategies and evaluation.
Sketris IS; Brown MG; Murphy AL
Healthc Pap; 2004; 4(3):36-45; discussion 68-72. PubMed ID: 15114068
[TBL] [Abstract][Full Text] [Related]
16. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
Morgan SG; Li W; Yau B; Persaud N
CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
[TBL] [Abstract][Full Text] [Related]
17. Prescription drug benefits for seniors and public/private collaboration.
Brekke M
Beginnings; 2002; 22(3):11. PubMed ID: 12046112
[No Abstract] [Full Text] [Related]
18. Medicaid prescription drug coverage: state efforts to control costs.
Gencarelli DM
NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
[TBL] [Abstract][Full Text] [Related]
19. What are fairness and consistency in a national pharmacy benefit?
Daniels N; Sabin JE
Med Care; 2001 Apr; 39(4):312-4. PubMed ID: 11329518
[No Abstract] [Full Text] [Related]
20. Can a health care system change?
Lexchin J
CMAJ; 1997 Sep; 157(5):507-8. PubMed ID: 9294383
[No Abstract] [Full Text] [Related]
[Next] [New Search]
